Peter Purgathofer looked over “Advanced Nanovaccines for Cancer Immunotherapy” by Nanasaheb Thorat, published in March by Springer Nature. On page 25, he found why we pay Springer the big bucks: [h…
I’m baffled by the number of people who had to ignore it (or see it and be ignored when they brought it up). Really makes you think about the quality of textbooks that such a thing could make it to print.
I’m baffled by the number of people who had to ignore it (or see it and be ignored when they brought it up). Really makes you think about the quality of textbooks that such a thing could make it to print.